https://magazine.pharmafile.com/daily0.5https://magazine.pharmafile.com/articlesdaily0.5https://magazine.pharmafile.com/articles/addressing-orphan-rare-and-paediatric-drug-development-through2024-05-22T14:08:15.000Zweekly0.6https://magazine.pharmafile.com/articles/advancing-treatment-options-for-rare-disease-patients2024-05-22T13:46:18.000Zweekly0.6https://magazine.pharmafile.com/articles/angle-and-astra-zeneca-sign-commercial-agreement2024-05-22T14:11:10.000Zweekly0.6https://magazine.pharmafile.com/articles/b121d8c9-182c-11ef-84d3-42010a8000152024-05-22T11:47:31.000Zweekly0.6https://magazine.pharmafile.com/articles/chmp-grants-positive-opinion-for-j-j-s-rybrevant-for-lung-cancer2024-05-22T14:16:13.000Zweekly0.6https://magazine.pharmafile.com/articles/comment-03db2024-05-22T14:17:25.000Zweekly0.6https://magazine.pharmafile.com/articles/contents-53652024-05-22T14:17:50.000Zweekly0.6https://magazine.pharmafile.com/articles/eko-health-s-ai-for-heart-failure-detection-approved-by-fda2024-05-22T14:11:56.000Zweekly0.6https://magazine.pharmafile.com/articles/fda-approves-pfizer-s-beqvez-for-haemophilia-b-treatment2024-05-22T14:16:52.000Zweekly0.6https://magazine.pharmafile.com/articles/fda-approves-roche-s-alecensa-as-lung-cancer-treatment2024-05-22T14:13:21.000Zweekly0.6https://magazine.pharmafile.com/articles/fda-to-review-gsk-s-meningococcal-vaccine-candidate2024-05-22T14:12:39.000Zweekly0.6https://magazine.pharmafile.com/articles/flypharma-vienna-20242024-05-22T14:18:06.000Zweekly0.6https://magazine.pharmafile.com/articles/international-women-s-day-remains-a-key-platform-to-keep-inspiri2024-05-22T12:17:06.000Zweekly0.6https://magazine.pharmafile.com/articles/mhra-approves-ascendis-pharma-s-yorvipath-for-hypoparathyroidism2024-05-22T14:15:17.000Zweekly0.6https://magazine.pharmafile.com/articles/overcoming-obstacles-in-rare-disease-treatment2024-05-22T13:52:43.000Zweekly0.6https://magazine.pharmafile.com/articles/pharmafile-af1b2024-05-22T14:18:32.000Zweekly0.6https://magazine.pharmafile.com/articles/pharmafocus-d86c2024-05-22T14:17:05.000Zweekly0.6https://magazine.pharmafile.com/articles/psychedelic-medicines-and-the-treatment-of-neurological-conditio2024-05-22T12:21:07.000Zweekly0.6https://magazine.pharmafile.com/articles/psychoactives-in-mental-health-treatment2024-05-22T12:23:27.000Zweekly0.6https://magazine.pharmafile.com/articles/reducing-unintended-pregnancy-rates-how-innovation-in-contracep2024-05-22T12:18:49.000Zweekly0.6https://magazine.pharmafile.com/articles/regeneron-and-mammoth-biosciences-to-collaborate-on-crispr-gene2024-05-22T14:09:48.000Zweekly0.6https://magazine.pharmafile.com/articles/reimagining-the-clinical-trial-paradigm-for-rare-disease-patient2024-05-22T14:00:17.000Zweekly0.6https://magazine.pharmafile.com/articles/samedan-13da2024-05-22T12:19:02.000Zweekly0.6https://magazine.pharmafile.com/articles/samedan-70e02024-05-22T11:45:56.000Zweekly0.6https://magazine.pharmafile.com/articles/transforming-access-the-power-of-patient-centricity-in-rare-dis2024-05-22T13:51:52.000Zweekly0.6https://magazine.pharmafile.com/articles/yourway2024-05-22T14:04:33.000Zweekly0.6https://magazine.pharmafile.com/articles/digital-opportunities-bf3b2024-01-05T15:05:20.000Zweekly0.6https://magazine.pharmafile.com/articles/introducing-our-new-digital-edition-website-e4ae2024-01-05T15:06:53.000Zweekly0.6https://magazine.pharmafile.com/articles/partnerships-and-collaborations-within-the-pharmaceutical-indust-fa3b2024-01-05T15:07:19.000Zweekly0.6https://magazine.pharmafile.com/articles/pharmafile-cf7d2024-01-05T15:07:40.000Zweekly0.6https://magazine.pharmafile.com/articles/pharmafocus-pharmafile-a85c2024-01-05T15:04:56.000Zweekly0.6https://magazine.pharmafile.com/articles/readership-breakdown-05422024-01-05T15:06:22.000Zweekly0.6https://magazine.pharmafile.com/articles/astellas-plans-investment-of-over-330m-for-new-facility-in-irel2023-10-02T12:15:23.000Zweekly0.6https://magazine.pharmafile.com/articles/astra-zeneca-and-daiichi-sankyo-share-positive-results-from-phase2023-10-03T11:48:08.000Zweekly0.6https://magazine.pharmafile.com/articles/bristol-myers-squibb-hosts-r-d-day-shares-new-research-and-deve2023-10-02T12:22:14.000Zweekly0.6https://magazine.pharmafile.com/articles/cepi-and-bio-n-tech-partner-for-development-of-m-rna-mpox-vaccine2023-10-02T12:20:46.000Zweekly0.6https://magazine.pharmafile.com/articles/comment2023-10-02T12:28:39.000Zweekly0.6https://magazine.pharmafile.com/articles/contents2023-10-02T12:29:29.000Zweekly0.6https://magazine.pharmafile.com/articles/eli-lilly-and-boehringer-ingelheim-s-jardiance-approved-by-fda-f2023-10-02T12:27:05.000Zweekly0.6https://magazine.pharmafile.com/articles/fda-approves-gsk-s-ojjaara-for-the-treatment-of-patients-with-my2023-10-02T12:25:57.000Zweekly0.6https://magazine.pharmafile.com/articles/gender-diversity-a-critical-component-in-clinical-trials2023-10-02T12:01:33.000Zweekly0.6https://magazine.pharmafile.com/articles/gsk-and-save-the-children-extend-partnership-to-increase-vaccina2023-10-02T12:17:52.000Zweekly0.6https://magazine.pharmafile.com/articles/intcr2023-10-02T12:29:49.000Zweekly0.6https://magazine.pharmafile.com/articles/menarini-group-s-orserdu-approved-by-european-commission-for-bre2023-10-02T12:25:11.000Zweekly0.6https://magazine.pharmafile.com/articles/merck-k-ga-a-and-exscientia-enter-collaboration-for-ai-drug-discov2023-10-02T12:18:47.000Zweekly0.6https://magazine.pharmafile.com/articles/pandemics-and-lessons-learnt-covid-19-and-cvd2023-10-02T12:12:51.000Zweekly0.6https://magazine.pharmafile.com/articles/pfizer-s-rsv-vaccine-recommended-by-cdc2023-10-02T12:28:06.000Zweekly0.6https://magazine.pharmafile.com/articles/phar-manovia-acquires-central-ner-vous-system-por-tfolio-from-sa2023-10-02T12:16:09.000Zweekly0.6https://magazine.pharmafile.com/articles/pharma-role2023-10-02T10:40:35.000Zweekly0.6https://magazine.pharmafile.com/articles/pharmafile-53732023-10-02T12:30:21.000Zweekly0.6https://magazine.pharmafile.com/articles/pharmafile-97662023-10-02T12:28:19.000Zweekly0.6https://magazine.pharmafile.com/articles/pharmafile-ad2023-10-02T12:02:01.000Zweekly0.6https://magazine.pharmafile.com/articles/pharmafile-events-03ab2023-10-02T10:42:27.000Zweekly0.6https://magazine.pharmafile.com/articles/prostate-cancer-new-screening-measures-and-decreasing-mortality2023-10-02T10:49:41.000Zweekly0.6https://magazine.pharmafile.com/articles/repairing-not-destroying-the-future-of-targeted-cancer-drug-des2023-10-02T11:04:37.000Zweekly0.6https://magazine.pharmafile.com/articles/samedan2023-10-02T10:41:01.000Zweekly0.6https://magazine.pharmafile.com/articles/taking-action-to-address-europe-s-non-communicable-disease-epide2023-10-02T12:14:57.000Zweekly0.6https://magazine.pharmafile.com/articles/the-ai-frontier-transforming-immunotherapy-with-intelligent-dru2023-10-02T11:10:13.000Zweekly0.6https://magazine.pharmafile.com/articles/the-changing-treatment-landscape-for-follicular-lymphoma2023-10-02T10:54:21.000Zweekly0.6https://magazine.pharmafile.com/articles/to-achieve-diversity-in-clinical-trials-patient-led-drug-develo2023-10-02T10:59:02.000Zweekly0.6https://magazine.pharmafile.com/articles/unicef-and-novo-nordisk-partner-to-prevent-global-childhood-obes2023-10-02T12:21:20.000Zweekly0.6https://magazine.pharmafile.com/articles/women-s-health-in-the-uk-an-in-depth-overview2023-10-02T12:09:51.000Zweekly0.6https://magazine.pharmafile.com/articles/addressing-inequalities-in-access-to-medicines-in-a-postcovid-world-the-challenge-of-cardiovascular-disease2023-03-02T05:44:29.000Zweekly0.6https://magazine.pharmafile.com/articles/ai-and-digital-tech-open-up-new-frontiers-in-neurology-research2023-03-02T05:44:29.000Zweekly0.6https://magazine.pharmafile.com/articles/ai-device-to-treat-chronic-pain-1116703108972023-03-02T05:44:34.000Zweekly0.6https://magazine.pharmafile.com/articles/aptar-pharma-completes-first-phase-of-616703108972023-03-02T05:44:39.000Zweekly0.6https://magazine.pharmafile.com/articles/astrazenecas-liver-cancer-treatment-gets-fda-approval2023-03-02T05:44:24.000Zweekly0.6https://magazine.pharmafile.com/articles/cancer-vaccine-may-be-available-by-20302023-03-02T05:44:25.000Zweekly0.6https://magazine.pharmafile.com/articles/contents-216703108972023-03-02T05:44:37.000Zweekly0.6https://magazine.pharmafile.com/articles/controversial-als-drug-approved-by-fda2023-03-02T05:44:22.000Zweekly0.6https://magazine.pharmafile.com/articles/diureticresistant-congestion-the-road-less-travelled-in-novel-treatments-for-chronic-heart-failure2023-03-02T05:44:28.000Zweekly0.6https://magazine.pharmafile.com/articles/ec-approves-car-t-cell-therapy-1216703108972023-03-02T05:44:38.000Zweekly0.6https://magazine.pharmafile.com/articles/editor-s-letter-316703108972023-03-02T05:44:36.000Zweekly0.6https://magazine.pharmafile.com/articles/fda-announces-recall-of-two-blood-pressure-pills-over-cancer-risk2023-03-02T05:44:26.000Zweekly0.6https://magazine.pharmafile.com/articles/fda-clears-gsk-s-boostrix-for-use-1416703108962023-03-02T05:44:26.000Zweekly0.6https://magazine.pharmafile.com/articles/furosemide-approved-by-fda-for-patients-with-chronic-heart-failure2023-03-02T05:44:24.000Zweekly0.6https://magazine.pharmafile.com/articles/gilead-and-macrogenics-partner-for-bispecific-antibody-development2023-03-02T05:44:25.000Zweekly0.6https://magazine.pharmafile.com/articles/helping-rare-diseases-emerge-from-the-shadows-to-take-centre-stage2023-03-02T05:44:32.000Zweekly0.6https://magazine.pharmafile.com/articles/how-rnabased-therapeutics-improve-care-and-benefit-patients2023-03-02T05:44:29.000Zweekly0.6https://magazine.pharmafile.com/articles/innovations-in-pharmaceutical-technology-3516703108972023-03-02T05:44:34.000Zweekly0.6https://magazine.pharmafile.com/articles/johnson-johnson-to-buy-abiomed-for-17bn2023-03-02T05:44:25.000Zweekly0.6https://magazine.pharmafile.com/articles/looking-to-the-future-of-neurology2023-03-02T05:44:31.000Zweekly0.6https://magazine.pharmafile.com/articles/merck-under-official-investigation-in-france-1716703108972023-03-02T05:44:35.000Zweekly0.6https://magazine.pharmafile.com/articles/merger-planned-between-biorad-and-qiagen2023-05-23T14:28:56.000Zweekly0.6https://magazine.pharmafile.com/articles/norstella-and-citeline-merge-to-create-5bn-pharma-tech-firm2023-03-02T05:44:22.000Zweekly0.6https://magazine.pharmafile.com/articles/oxford-biotech-purchased-by-abb-vie-for-916703108972023-03-02T05:44:37.000Zweekly0.6https://magazine.pharmafile.com/articles/pharma-times-3616703108972023-03-02T05:44:38.000Zweekly0.6https://magazine.pharmafile.com/articles/pharmafile-016703108972023-05-23T14:13:21.000Zweekly0.6https://magazine.pharmafile.com/articles/pharmafile-2716703108972023-03-02T05:44:35.000Zweekly0.6https://magazine.pharmafile.com/articles/pharmafile-events2023-03-02T05:44:28.000Zweekly0.6https://magazine.pharmafile.com/articles/potentially-cancerstopping-pill-given-to-first-patient2023-03-02T05:44:27.000Zweekly0.6https://magazine.pharmafile.com/articles/prime-vigilance-116703108972023-03-02T05:44:34.000Zweekly0.6https://magazine.pharmafile.com/articles/rising-to-the-unique-challenges-of-rare-diseases2023-03-02T05:44:27.000Zweekly0.6https://magazine.pharmafile.com/articles/samedan-ltd-416703108972023-03-02T05:44:32.000Zweekly0.6https://magazine.pharmafile.com/articles/the-changing-landscape-of-rare-disease-research2023-03-02T05:44:31.000Zweekly0.6https://magazine.pharmafile.com/articles/the-importance-of-treating-tbis-early2023-03-02T05:44:30.000Zweekly0.6https://magazine.pharmafile.com/articles/the-power-of-partnership-collaborating-with-patient-advocacy-organisations-for-better-clinical-research2023-03-02T05:44:32.000Zweekly0.6https://magazine.pharmafile.com/articles/unmet-needs-in-clinical-tr-ials-for-neurological-conditions2023-03-02T05:44:30.000Zweekly0.6https://magazine.pharmafile.com/articles/us-pharmacies-agree-to-10bn-opioid-1916703108972023-03-02T05:44:36.000Zweekly0.6https://magazine.pharmafile.com/articles/a-targeted-approach-to-developing-targeted-916691061162023-03-02T05:43:10.000Zweekly0.6https://magazine.pharmafile.com/articles/a-technological-revolution-that-works-for-316691061162023-03-02T05:43:13.000Zweekly0.6https://magazine.pharmafile.com/articles/aptar-pharma-1416691061152023-03-02T05:43:02.000Zweekly0.6https://magazine.pharmafile.com/articles/breathing-new-life-into-respiratory-research-016691061152023-03-02T05:43:04.000Zweekly0.6https://magazine.pharmafile.com/articles/chelsea-harbour-hotel-116691061162023-03-02T05:43:07.000Zweekly0.6https://magazine.pharmafile.com/articles/communiqu-2216691061162023-03-02T05:43:09.000Zweekly0.6https://magazine.pharmafile.com/articles/contents-216691061152023-03-02T05:43:02.000Zweekly0.6https://magazine.pharmafile.com/articles/dose-and-deliver-how-pmd-is-are-1316691061162023-03-02T05:43:13.000Zweekly0.6https://magazine.pharmafile.com/articles/embrace-disruption-the-changing-landscape-of-816691061162023-03-02T05:43:12.000Zweekly0.6https://magazine.pharmafile.com/articles/embracing-transdermal-technologies-2116691061172023-03-02T05:43:15.000Zweekly0.6https://magazine.pharmafile.com/articles/flypharma-conference-europe-2022-2716691061162023-03-02T05:43:07.000Zweekly0.6https://magazine.pharmafile.com/articles/improving-outcomes-in-idiopathic-pulmonary-fibrosis-1516691061162023-03-02T05:43:08.000Zweekly0.6https://magazine.pharmafile.com/articles/new-treatments-and-new-challenges-the-716691061162023-03-02T05:43:14.000Zweekly0.6https://magazine.pharmafile.com/articles/nhs-waiting-lists-the-second-healthcare-1116691061162023-03-02T05:43:11.000Zweekly0.6https://magazine.pharmafile.com/articles/pain-management-and-pharmaceutical-compounding-1916691061172023-03-02T05:43:16.000Zweekly0.6https://magazine.pharmafile.com/articles/pharma-times-1816691061152023-03-02T05:43:01.000Zweekly0.6https://magazine.pharmafile.com/articles/pharmafile-2516691061162023-03-02T05:43:05.000Zweekly0.6https://magazine.pharmafile.com/articles/pmggroup-416691061152023-03-02T05:43:03.000Zweekly0.6https://magazine.pharmafile.com/articles/q-a-1216691061162023-03-02T05:43:11.000Zweekly0.6https://magazine.pharmafile.com/articles/q-a-1716691061172023-03-02T05:43:15.000Zweekly0.6https://magazine.pharmafile.com/articles/q-a-516691061172023-03-02T05:43:14.000Zweekly0.6https://magazine.pharmafile.com/articles/qic-dermatology-616691061162023-03-02T05:43:06.000Zweekly0.6https://magazine.pharmafile.com/articles/rare-diseases-and-exceptional-solutions-2316691061172023-03-02T05:43:14.000Zweekly0.6https://magazine.pharmafile.com/articles/rock2-the-top-the-future-of-1616691061162023-03-02T05:43:09.000Zweekly0.6https://magazine.pharmafile.com/articles/samedan-2616691061162023-03-02T05:43:06.000Zweekly0.6https://magazine.pharmafile.com/articles/samedan-ltd-2016691061152023-03-02T05:43:04.000Zweekly0.6https://magazine.pharmafile.com/articles/supporting-the-challenges-of-innovative-systemic-1016691061162023-03-02T05:43:10.000Zweekly0.6https://magazine.pharmafile.com/articles/the-combination-treatment-challenge-2416691061162023-03-02T05:43:08.000Zweekly0.6https://magazine.pharmafile.com/articles/a-bold-and-ambitious-plan-harnessing-716691059122023-03-02T05:43:16.000Zweekly0.6https://magazine.pharmafile.com/articles/charting-the-course-to-2022-316691059122023-03-02T05:43:15.000Zweekly0.6https://magazine.pharmafile.com/articles/contents-216691059122023-03-02T05:43:07.000Zweekly0.6https://magazine.pharmafile.com/articles/cumulative-life-course-impairment-the-unforeseen-1816691059122023-03-02T05:43:18.000Zweekly0.6https://magazine.pharmafile.com/articles/delivering-transformational-data-analysis-for-infectious-916691059122023-03-02T05:43:16.000Zweekly0.6https://magazine.pharmafile.com/articles/dermatologically-speaking-finding-new-treatments-for-1916691059122023-03-02T05:43:08.000Zweekly0.6https://magazine.pharmafile.com/articles/every-number-has-a-face-are-1416691059122023-03-02T05:43:10.000Zweekly0.6https://magazine.pharmafile.com/articles/icon-2416691059112023-03-02T05:43:04.000Zweekly0.6https://magazine.pharmafile.com/articles/insight-and-oversight-making-the-most-2016691059122023-03-02T05:43:09.000Zweekly0.6https://magazine.pharmafile.com/articles/not-so-rare-diseases-the-cumulative-1516691059122023-03-02T05:43:17.000Zweekly0.6https://magazine.pharmafile.com/articles/pharma-times-416691059122023-03-02T05:43:05.000Zweekly0.6https://magazine.pharmafile.com/articles/pharmafile-016691059112023-03-02T05:43:01.000Zweekly0.6https://magazine.pharmafile.com/articles/pharmafile-1216691059112023-03-02T05:43:02.000Zweekly0.6https://magazine.pharmafile.com/articles/pme-1716691059112023-03-02T05:43:04.000Zweekly0.6https://magazine.pharmafile.com/articles/q-a-516691059132023-03-02T05:43:19.000Zweekly0.6https://magazine.pharmafile.com/articles/rare-disease-and-orphan-medicines-1316691059122023-03-02T05:43:18.000Zweekly0.6https://magazine.pharmafile.com/articles/redbow-consulting-116691059112023-03-02T05:43:01.000Zweekly0.6https://magazine.pharmafile.com/articles/redbow-consulting-group-816691059122023-03-02T05:43:06.000Zweekly0.6https://magazine.pharmafile.com/articles/resisting-change-the-pathway-to-better-616691059122023-03-02T05:43:18.000Zweekly0.6https://magazine.pharmafile.com/articles/samedan-2316691059112023-03-02T05:43:03.000Zweekly0.6https://magazine.pharmafile.com/articles/scratching-the-surface-of-eczema-care-1616691059122023-03-02T05:43:06.000Zweekly0.6https://magazine.pharmafile.com/articles/supporting-dermatology-and-oncology-services-to-2216691059122023-03-02T05:43:17.000Zweekly0.6https://magazine.pharmafile.com/articles/supporting-rare-neurological-disease-patients-during-1016691059122023-03-02T05:43:09.000Zweekly0.6https://magazine.pharmafile.com/articles/the-pain-keeps-me-awake-at-2116691059122023-03-02T05:43:10.000Zweekly0.6https://magazine.pharmafile.com/articles/treatable-untreatable-undetermined-overcoming-rare-disease-1116691059122023-03-02T05:43:17.000Zweekly0.6https://magazine.pharmafile.com/categories/infectious-diseases2023-09-20T08:06:39.000Zweekly0.6https://magazine.pharmafile.com/categories/rare-diseases2024-05-22T14:05:26.000Zweekly0.6https://magazine.pharmafile.com/categories/dermatology2023-09-20T08:08:59.000Zweekly0.6https://magazine.pharmafile.com/categories/oncology2023-10-09T14:37:16.000Zweekly0.6https://magazine.pharmafile.com/categories/respiratory2023-10-09T14:38:30.000Zweekly0.6https://magazine.pharmafile.com/categories/pain2023-10-09T14:40:54.000Zweekly0.6https://magazine.pharmafile.com/categories/neurology2024-05-22T12:22:00.000Zweekly0.6https://magazine.pharmafile.com/categories/cardiovascular2023-10-09T14:44:20.000Zweekly0.6https://magazine.pharmafile.com/categories/news2024-05-22T14:16:52.000Zweekly0.6https://magazine.pharmafile.com/categories/womens-health2024-05-22T12:17:37.000Zweekly0.6https://magazine.pharmafile.com/collectionsdaily0.5https://magazine.pharmafile.com/collections/pharmafile-v76-spring-20242024-05-22T14:18:47.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v76-spring-2024/flypharma-vienna-20242024-05-22T14:18:06.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v76-spring-2024/contents-53652024-05-22T14:17:50.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v76-spring-2024/comment-03db2024-05-22T14:17:25.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v76-spring-2024/pharmafile-af1b2024-05-22T14:18:32.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v76-spring-2024/pharmafocus-d86c2024-05-22T14:17:05.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v76-spring-2024/chmp-grants-positive-opinion-for-j-j-s-rybrevant-for-lung-cancer2024-05-22T14:16:13.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v76-spring-2024/mhra-approves-ascendis-pharma-s-yorvipath-for-hypoparathyroidism2024-05-22T14:15:17.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v76-spring-2024/fda-approves-roche-s-alecensa-as-lung-cancer-treatment2024-05-22T14:13:21.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v76-spring-2024/fda-approves-pfizer-s-beqvez-for-haemophilia-b-treatment2024-05-22T14:16:52.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v76-spring-2024/eko-health-s-ai-for-heart-failure-detection-approved-by-fda2024-05-22T14:11:56.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v76-spring-2024/regeneron-and-mammoth-biosciences-to-collaborate-on-crispr-gene2024-05-22T14:09:48.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v76-spring-2024/fda-to-review-gsk-s-meningococcal-vaccine-candidate2024-05-22T14:12:39.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v76-spring-2024/angle-and-astra-zeneca-sign-commercial-agreement2024-05-22T14:11:10.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v76-spring-2024/addressing-orphan-rare-and-paediatric-drug-development-through2024-05-22T14:08:15.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v76-spring-2024/reimagining-the-clinical-trial-paradigm-for-rare-disease-patient2024-05-22T14:00:17.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v76-spring-2024/yourway2024-05-22T14:04:33.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v76-spring-2024/overcoming-obstacles-in-rare-disease-treatment2024-05-22T13:52:43.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v76-spring-2024/transforming-access-the-power-of-patient-centricity-in-rare-dis2024-05-22T13:51:52.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v76-spring-2024/psychoactives-in-mental-health-treatment2024-05-22T12:23:27.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v76-spring-2024/psychedelic-medicines-and-the-treatment-of-neurological-conditio2024-05-22T12:21:07.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v76-spring-2024/advancing-treatment-options-for-rare-disease-patients2024-05-22T13:46:18.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v76-spring-2024/reducing-unintended-pregnancy-rates-how-innovation-in-contracep2024-05-22T12:18:49.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v76-spring-2024/samedan-13da2024-05-22T12:19:02.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v76-spring-2024/international-women-s-day-remains-a-key-platform-to-keep-inspiri2024-05-22T12:17:06.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v76-spring-2024/samedan-70e02024-05-22T11:45:56.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v76-spring-2024/b121d8c9-182c-11ef-84d3-42010a8000152024-05-22T11:47:31.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-20242024-01-05T15:07:53.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-2024/pharmafile-cf7d2024-01-05T15:07:40.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-2024/introducing-our-new-digital-edition-website-e4ae2024-01-05T15:06:53.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-2024/partnerships-and-collaborations-within-the-pharmaceutical-indust-fa3b2024-01-05T15:07:19.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-2024/readership-breakdown-05422024-01-05T15:06:22.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-2024/digital-opportunities-bf3b2024-01-05T15:05:20.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-2024/pharmafocus-pharmafile-a85c2024-01-05T15:04:56.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-autumn-20232023-10-02T14:20:14.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-autumn-2023/contents2023-10-02T12:29:29.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-autumn-2023/intcr2023-10-02T12:29:49.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-autumn-2023/comment2023-10-02T12:28:39.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-autumn-2023/pharmafile-53732023-10-02T12:30:21.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-autumn-2023/pharmafile-97662023-10-02T12:28:19.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-autumn-2023/pfizer-s-rsv-vaccine-recommended-by-cdc2023-10-02T12:28:06.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-autumn-2023/eli-lilly-and-boehringer-ingelheim-s-jardiance-approved-by-fda-f2023-10-02T12:27:05.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-autumn-2023/fda-approves-gsk-s-ojjaara-for-the-treatment-of-patients-with-my2023-10-02T12:25:57.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-autumn-2023/menarini-group-s-orserdu-approved-by-european-commission-for-bre2023-10-02T12:25:11.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-autumn-2023/astra-zeneca-and-daiichi-sankyo-share-positive-results-from-phase2023-10-03T11:48:08.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-autumn-2023/cepi-and-bio-n-tech-partner-for-development-of-m-rna-mpox-vaccine2023-10-02T12:20:46.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-autumn-2023/bristol-myers-squibb-hosts-r-d-day-shares-new-research-and-deve2023-10-02T12:22:14.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-autumn-2023/merck-k-ga-a-and-exscientia-enter-collaboration-for-ai-drug-discov2023-10-02T12:18:47.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-autumn-2023/unicef-and-novo-nordisk-partner-to-prevent-global-childhood-obes2023-10-02T12:21:20.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-autumn-2023/phar-manovia-acquires-central-ner-vous-system-por-tfolio-from-sa2023-10-02T12:16:09.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-autumn-2023/astellas-plans-investment-of-over-330m-for-new-facility-in-irel2023-10-02T12:15:23.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-autumn-2023/gsk-and-save-the-children-extend-partnership-to-increase-vaccina2023-10-02T12:17:52.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-autumn-2023/taking-action-to-address-europe-s-non-communicable-disease-epide2023-10-02T12:14:57.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-autumn-2023/women-s-health-in-the-uk-an-in-depth-overview2023-10-02T12:09:51.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-autumn-2023/gender-diversity-a-critical-component-in-clinical-trials2023-10-02T12:01:33.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-autumn-2023/pandemics-and-lessons-learnt-covid-19-and-cvd2023-10-02T12:12:51.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-autumn-2023/pharmafile-ad2023-10-02T12:02:01.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-autumn-2023/the-ai-frontier-transforming-immunotherapy-with-intelligent-dru2023-10-02T11:10:13.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-autumn-2023/repairing-not-destroying-the-future-of-targeted-cancer-drug-des2023-10-02T11:04:37.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-autumn-2023/to-achieve-diversity-in-clinical-trials-patient-led-drug-develo2023-10-02T10:59:02.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-autumn-2023/the-changing-treatment-landscape-for-follicular-lymphoma2023-10-02T10:54:21.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-autumn-2023/prostate-cancer-new-screening-measures-and-decreasing-mortality2023-10-02T10:49:41.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-autumn-2023/pharma-role2023-10-02T10:40:35.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-autumn-2023/samedan2023-10-02T10:41:01.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-autumn-2023/pharmafile-events-03ab2023-10-02T10:42:27.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-20222023-09-20T12:55:27.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/norstella-and-citeline-merge-to-create-5bn-pharma-tech-firm2023-03-02T05:44:22.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/controversial-als-drug-approved-by-fda2023-03-02T05:44:22.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/merger-planned-between-biorad-and-qiagen2023-05-23T14:28:56.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/astrazenecas-liver-cancer-treatment-gets-fda-approval2023-03-02T05:44:24.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/furosemide-approved-by-fda-for-patients-with-chronic-heart-failure2023-03-02T05:44:24.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/cancer-vaccine-may-be-available-by-20302023-03-02T05:44:25.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/johnson-johnson-to-buy-abiomed-for-17bn2023-03-02T05:44:25.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/gilead-and-macrogenics-partner-for-bispecific-antibody-development2023-03-02T05:44:25.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/fda-announces-recall-of-two-blood-pressure-pills-over-cancer-risk2023-03-02T05:44:26.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/fda-clears-gsk-s-boostrix-for-use-1416703108962023-03-02T05:44:26.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/potentially-cancerstopping-pill-given-to-first-patient2023-03-02T05:44:27.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/rising-to-the-unique-challenges-of-rare-diseases2023-03-02T05:44:27.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/pharmafile-events2023-03-02T05:44:28.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/diureticresistant-congestion-the-road-less-travelled-in-novel-treatments-for-chronic-heart-failure2023-03-02T05:44:28.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/ai-and-digital-tech-open-up-new-frontiers-in-neurology-research2023-03-02T05:44:29.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/how-rnabased-therapeutics-improve-care-and-benefit-patients2023-03-02T05:44:29.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/addressing-inequalities-in-access-to-medicines-in-a-postcovid-world-the-challenge-of-cardiovascular-disease2023-03-02T05:44:29.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/unmet-needs-in-clinical-tr-ials-for-neurological-conditions2023-03-02T05:44:30.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/the-importance-of-treating-tbis-early2023-03-02T05:44:30.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/looking-to-the-future-of-neurology2023-03-02T05:44:31.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/the-changing-landscape-of-rare-disease-research2023-03-02T05:44:31.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/samedan-ltd-416703108972023-03-02T05:44:32.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/the-power-of-partnership-collaborating-with-patient-advocacy-organisations-for-better-clinical-research2023-03-02T05:44:32.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/helping-rare-diseases-emerge-from-the-shadows-to-take-centre-stage2023-03-02T05:44:32.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/pharmafile-016703108972023-05-23T14:13:21.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/prime-vigilance-116703108972023-03-02T05:44:34.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/innovations-in-pharmaceutical-technology-3516703108972023-03-02T05:44:34.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/ai-device-to-treat-chronic-pain-1116703108972023-03-02T05:44:34.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/merck-under-official-investigation-in-france-1716703108972023-03-02T05:44:35.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/pharmafile-2716703108972023-03-02T05:44:35.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/us-pharmacies-agree-to-10bn-opioid-1916703108972023-03-02T05:44:36.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/editor-s-letter-316703108972023-03-02T05:44:36.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/contents-216703108972023-03-02T05:44:37.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/oxford-biotech-purchased-by-abb-vie-for-916703108972023-03-02T05:44:37.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/ec-approves-car-t-cell-therapy-1216703108972023-03-02T05:44:38.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/pharma-times-3616703108972023-03-02T05:44:38.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v74-autumn-2022/aptar-pharma-completes-first-phase-of-616703108972023-03-02T05:44:39.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v73-summer-20222023-09-20T12:55:18.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v73-summer-2022/pharma-times-1816691061152023-03-02T05:43:01.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v73-summer-2022/contents-216691061152023-03-02T05:43:02.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v73-summer-2022/aptar-pharma-1416691061152023-03-02T05:43:02.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v73-summer-2022/pmggroup-416691061152023-03-02T05:43:03.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v73-summer-2022/breathing-new-life-into-respiratory-research-016691061152023-03-02T05:43:04.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v73-summer-2022/samedan-ltd-2016691061152023-03-02T05:43:04.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v73-summer-2022/pharmafile-2516691061162023-03-02T05:43:05.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v73-summer-2022/qic-dermatology-616691061162023-03-02T05:43:06.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v73-summer-2022/samedan-2616691061162023-03-02T05:43:06.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v73-summer-2022/flypharma-conference-europe-2022-2716691061162023-03-02T05:43:07.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v73-summer-2022/chelsea-harbour-hotel-116691061162023-03-02T05:43:07.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v73-summer-2022/improving-outcomes-in-idiopathic-pulmonary-fibrosis-1516691061162023-03-02T05:43:08.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v73-summer-2022/the-combination-treatment-challenge-2416691061162023-03-02T05:43:08.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v73-summer-2022/communiqu-2216691061162023-03-02T05:43:09.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v73-summer-2022/rock2-the-top-the-future-of-1616691061162023-03-02T05:43:09.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v73-summer-2022/a-targeted-approach-to-developing-targeted-916691061162023-03-02T05:43:10.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v73-summer-2022/supporting-the-challenges-of-innovative-systemic-1016691061162023-03-02T05:43:10.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v73-summer-2022/q-a-1216691061162023-03-02T05:43:11.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v73-summer-2022/nhs-waiting-lists-the-second-healthcare-1116691061162023-03-02T05:43:11.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v73-summer-2022/embrace-disruption-the-changing-landscape-of-816691061162023-03-02T05:43:12.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v73-summer-2022/a-technological-revolution-that-works-for-316691061162023-03-02T05:43:13.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v73-summer-2022/dose-and-deliver-how-pmd-is-are-1316691061162023-03-02T05:43:13.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v73-summer-2022/new-treatments-and-new-challenges-the-716691061162023-03-02T05:43:14.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v73-summer-2022/rare-diseases-and-exceptional-solutions-2316691061172023-03-02T05:43:14.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v73-summer-2022/q-a-516691061172023-03-02T05:43:14.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v73-summer-2022/q-a-1716691061172023-03-02T05:43:15.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v73-summer-2022/embracing-transdermal-technologies-2116691061172023-03-02T05:43:15.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v73-summer-2022/pain-management-and-pharmaceutical-compounding-1916691061172023-03-02T05:43:16.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v72-winter-20212023-09-20T12:55:03.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v72-winter-2021/pharmafile-016691059112023-03-02T05:43:01.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v72-winter-2021/redbow-consulting-116691059112023-03-02T05:43:01.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v72-winter-2021/pharmafile-1216691059112023-03-02T05:43:02.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v72-winter-2021/samedan-2316691059112023-03-02T05:43:03.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v72-winter-2021/icon-2416691059112023-03-02T05:43:04.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v72-winter-2021/pme-1716691059112023-03-02T05:43:04.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v72-winter-2021/pharma-times-416691059122023-03-02T05:43:05.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v72-winter-2021/redbow-consulting-group-816691059122023-03-02T05:43:06.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v72-winter-2021/scratching-the-surface-of-eczema-care-1616691059122023-03-02T05:43:06.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v72-winter-2021/contents-216691059122023-03-02T05:43:07.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v72-winter-2021/dermatologically-speaking-finding-new-treatments-for-1916691059122023-03-02T05:43:08.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v72-winter-2021/insight-and-oversight-making-the-most-2016691059122023-03-02T05:43:09.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v72-winter-2021/supporting-rare-neurological-disease-patients-during-1016691059122023-03-02T05:43:09.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v72-winter-2021/the-pain-keeps-me-awake-at-2116691059122023-03-02T05:43:10.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v72-winter-2021/every-number-has-a-face-are-1416691059122023-03-02T05:43:10.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v72-winter-2021/charting-the-course-to-2022-316691059122023-03-02T05:43:15.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v72-winter-2021/delivering-transformational-data-analysis-for-infectious-916691059122023-03-02T05:43:16.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v72-winter-2021/a-bold-and-ambitious-plan-harnessing-716691059122023-03-02T05:43:16.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v72-winter-2021/supporting-dermatology-and-oncology-services-to-2216691059122023-03-02T05:43:17.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v72-winter-2021/treatable-untreatable-undetermined-overcoming-rare-disease-1116691059122023-03-02T05:43:17.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v72-winter-2021/not-so-rare-diseases-the-cumulative-1516691059122023-03-02T05:43:17.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v72-winter-2021/cumulative-life-course-impairment-the-unforeseen-1816691059122023-03-02T05:43:18.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v72-winter-2021/rare-disease-and-orphan-medicines-1316691059122023-03-02T05:43:18.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v72-winter-2021/resisting-change-the-pathway-to-better-616691059122023-03-02T05:43:18.000Zweekly0.6https://magazine.pharmafile.com/collections/pharmafile-v72-winter-2021/q-a-516691059132023-03-02T05:43:19.000Zweekly0.6